vancomycin

vancomycin
Name	Vancomycin
Routes	Intravenous, oral, intraperitoneal
Metabolism	Minimal
Elimination	Renal
Cas number	1404-90-6

vancomycin

Vancomycin is a glycopeptide antibiotic used to treat serious Gram-positive bacterial infections. It is indicated for severe infections caused by Staphylococcus aureus, Clostridioides difficile, and Enterococcus species when other agents are unsuitable, and is central to stewardship protocols in hospitals such as Mayo Clinic, Johns Hopkins Hospital, and Massachusetts General Hospital. Clinical guidelines from organizations including the Infectious Diseases Society of America and the World Health Organization inform its use in settings ranging from intensive care units at Cleveland Clinic to outpatient parenteral antibiotic therapy programs.

Medical uses

Vancomycin is primarily employed for complicated infections such as bloodstream infections, endocarditis, osteomyelitis, and hospital-acquired pneumonia caused by resistant Gram-positive organisms, with dosing guided by recommendations from Centers for Disease Control and Prevention, National Institutes of Health, and regional bodies like the European Medicines Agency. It is the first-line intravenous option in many protocols for suspected or confirmed methicillin-resistant Staphylococcus aureus infections used in treatment pathways at institutions including Veterans Health Administration hospitals and tertiary centers such as UCSF Medical Center. Oral vancomycin is used for severe Clostridioides difficile colitis in guidelines promulgated by panels convened by American College of Gastroenterology and deployed in clinical practice at systems like Kaiser Permanente. Specialist societies including the Society of Infectious Diseases Pharmacists and the American Society of Health-System Pharmacists provide therapeutic monitoring strategies used at centers such as Mount Sinai Health System.

Mechanism of action

Vancomycin exerts bactericidal activity by binding to the d-alanyl–d-alanine termini of cell wall precursors, inhibiting peptidoglycan polymerization; this biochemical interaction is discussed in literature from research groups at Harvard Medical School, Stanford University, and University of Oxford. Structural studies from laboratories affiliated with Max Planck Institute and Cold Spring Harbor Laboratory elucidated its three-dimensional binding and blockade of transglycosylation, complementing mechanistic reviews published by teams at National Institutes of Health and Imperial College London. The mechanism underpins clinical choices made by stewardship committees at Johns Hopkins Hospital and infection control teams at Guy's and St Thomas' NHS Foundation Trust when selecting agents against resistant Gram-positive pathogens such as Enterococcus faecalis and Staphylococcus aureus.

Pharmacokinetics and dosing

Pharmacokinetic parameters—absorption negligible orally, distribution to extracellular fluid, minimal metabolism, renal elimination—are summarized in monographs used by pharmacy departments at University College London Hospitals and dosing nomograms developed at Vanderbilt University Medical Center. Therapeutic drug monitoring protocols endorsed by American Society of Health-System Pharmacists and implemented at centers like UCLA Health and Ohio State University Wexner Medical Center aim for target trough concentrations historically recommended by the Infectious Diseases Society of America; recent pharmacodynamic models from investigators at University of Pennsylvania and University of Michigan promote AUC-guided dosing. Special populations managed in clinics at Boston Children's Hospital, Children's Hospital of Philadelphia, and Great Ormond Street Hospital require neonatal and pediatric adjustments informed by studies from National Institute for Health and Care Research and dosing guidance used in transplant services at Fred Hutchinson Cancer Center.

Adverse effects and toxicity

Notable adverse effects include nephrotoxicity, ototoxicity, and infusion-related reactions such as "red man syndrome," described in case series from Mayo Clinic and pharmacovigilance reports to agencies like Food and Drug Administration and European Medicines Agency. Risk mitigation strategies used at Cleveland Clinic and Royal College of Physicians–affiliated hospitals emphasize monitoring serum creatinine and auditory function, with dosing adjustments in renal impairment guided by protocols at Toronto General Hospital and St Thomas' Hospital. Interactions with agents such as aminoglycosides and selected immunosuppressants are managed in multidisciplinary teams at Memorial Sloan Kettering Cancer Center and National Cancer Institute transplant units.

Resistance

Resistance mechanisms—particularly alteration of the d-alanyl–d-alanine target to d-alanyl–d-lactate mediated by van gene clusters—were characterized in studies from University of California, San Diego, Institut Pasteur, and University of Copenhagen. Clinical emergence of vancomycin-resistant Enterococcus (VRE) has been reported in surveillance programs coordinated by Centers for Disease Control and Prevention and national reference laboratories such as Public Health England, leading to treatment algorithm changes at hospitals including Mount Sinai Hospital and Addenbrooke's Hospital. Molecular epidemiology from research centers at Wellcome Sanger Institute, Broad Institute, and Karolinska Institutet tracks plasmid-mediated spread, while alternative therapies from groups at AstraZeneca, Pfizer, and biotech firms have been evaluated in trials at centers like Mayo Clinic and Johns Hopkins Hospital.

History and development

Vancomycin was discovered in soil-derived actinomycetes and developed in mid-20th century antimicrobial programs documented in historical reviews from Rockefeller University, Harvard Medical School, and archival records at US National Library of Medicine. Early clinical deployment and subsequent refinement of indications involved clinicians at institutions such as Massachusetts General Hospital and researchers at Eli Lilly and Company and Merck & Co.. Landmark policy decisions incorporating vancomycin into hospital formularies were influenced by panels convened by World Health Organization and national advisory committees at Food and Drug Administration and Public Health England.

Production and formulations

Commercial manufacturing involves fermentation of producing strains with downstream purification and formulation steps performed by pharmaceutical manufacturers including Novartis, GlaxoSmithKline, and generic producers supplying hospital pharmacies at networks like Intermountain Healthcare and National Health Service (England). Formulations include intravenous preparations for systemic infections and oral capsules or solutions for gastrointestinal indications, stocked in pharmacies at Johns Hopkins Hospital Pharmacy and compounding services at Cleveland Clinic Pharmacy. Ongoing development of liposomal and alternative delivery systems has been reported from collaborations between academic groups at MIT and industry partners such as Johnson & Johnson.

Category:Antibiotics